AIRNA Raises Oversubscribed $155 Million Series B Financing to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin Deficiency and Future Pipeline — Airna Financing led by Venrock Healthcare Capital Partners with co-lead Forbion Growth, and participation from RTW Investments, Nextech Invest, and other new

$155M Series B investment into preclin #ADAR Therapeutics Co #Airna, highlighting strong interest in modality despite challenging biotech environment.

$ to be used to advance AATD candidate into clinc + develop cardiometabolic candidates: airna.com/news/airna-r... #ProQR #WaveLifeSciences #Korro